New York City / Prague — May 14, 2025 — Stimvia, a pioneering medtech company from the Czech Republic developing non-invasive neuromodulation therapies for overactive bladder (OAB), has successfully graduated from the prestigious Endless Frontier Labs (EFL) program at NYU Stern School of Business.
This achievement marks a significant milestone in Stimvia’s journey as it prepares to enter the U.S. healthcare market, with FDA clearance pending for its breakthrough device, URIS®.
Chosen from 70,000+ Startups Worldwide
Stimvia was selected from over 70,000 science and tech startups spanning more than 120 countries and regions to join the 2024–25 EFL cohort. Out of 100 accepted companies, only 55—including Stimvia—successfully completed the program, which is designed to support and scale globally impactful ventures.
“This experience gave us sharper insight into what it takes to win in the U.S. market,” said Lukas Doskocil, CEO of Stimvia. “Over 3,500 clinics still offer patients a 23-year-old technology — we’re here to change that. With direct, highly relevant feedback from mentors at EFL, we refined our value proposition to deliver a revolutionary solution. One that simplifies clinic operations and, above all, dramatically improves patient outcomes. We’re leaving the program ready to bring real innovation where it’s needed most.”
URIS®: A Non-Invasive Alternative to Surgery and Drugs
Stimvia’s flagship product, URIS®, is the first non-invasive closed-loop neuromodulation system developed for the treatment of OAB without the need for surgery or pharmaceutical intervention. The system uses eTNM® (peroneal transcutaneous electrical nerve stimulation), a proprietary technology that delivers targeted neurostimulation to restore proper brain-bladder signaling.
Clinical studies have demonstrated that over 90% of patients experience significant symptom relief using URIS®, with a strong safety profile and no serious adverse events reported.
MDR Certification and Global Market Readiness
In 2024, Stimvia received Medical Device Regulation (MDR) certification from TÜV SÜD for both its eTNM® and minimally invasive PTNS methods — making it the first company in Europe, and only the third globally, to hold MDR approval for both techniques. The only other companies with such recognition are Medtronic and Laborie.
This certification not only confirms the safety and efficacy of Stimvia’s technology but also paves the way for reimbursement in key global markets.
Tapping Into a $5B+ Market
With the U.S. neuromodulation market for OAB alone estimated at nearly $5 billion annually, Stimvia is strategically positioned to offer an innovative, accessible alternative to outdated treatment options. The broader economic burden of OAB treatment across the U.S. and Europe exceeds $117 billion per year, underscoring the urgent need for better solutions.
About Stimvia
Stimvia is a Czech medical technology company focused on the development and commercialization of non-invasive neuromodulation therapies for chronic conditions. Its flagship system, URIS®, uses a proprietary method called eTNM® (peroneal transcutaneous neuromodulation) — the first non-invasive technique proven to stimulate deep brain structures responsible for bladder regulation and other neurological functions.
In addition to its proven effectiveness for OAB, URIS® has shown promising results in early studies for Parkinson’s disease. The company’s technology portfolio is protected by over 100 international patents across Europe, the U.S., Japan, and other key markets.
Stimvia holds MDR medical device certification from TÜV SÜD, placing it among a select group of global medtech innovators meeting the EU’s highest regulatory standards.
Media Contact
Zuzana Kasparova
📧 media@stimvia.com
📞 +420 773 068 497
Let me know if you’d like a shortened version for the homepage or blog, or if you want this turned into a downloadable press release PDF.